DOCS

As suggested in previous posts, we have taken advantage of Doximity’s recent share price compression to add to our position. The shares were weak this morning, August 30, 2021 and so we doubled the size of our position by buying 225 additional shares at a price of $77.99/share. The purchase cost $!7,230. As indicated in…

To access this post, you must subscribe.

Read More

After several days of risk-on bias, the market has reversed to some degree, today, Thursday, August 26, 2021. As I write this, the Nasdaq Index has declined by about 0.64%. That is about the same as the change in the S&P. The Cloud and Software indices are performing a bit better and were both down…

To access this post, you must subscribe.

Read More

As mentioned in past portfolio commentaries, our holding in PTC was simply too small in terms of our portfolio management methodology. While we felt that the reaction of PTC to its most recent earnings release and guidance left the shares at a bargain valuation with an EV/S of just 8.7X, we wanted to eliminate an…

To access this post, you must subscribe.

Read More

Upstart It is just getting started Upstart reported its results after the close on 8/10. To call the results a blow-out would not do justice to the results. I am not sure I have ever had the opportunity to follow and to own a name with quite such a rapid growth rate. But besides the…

To access this post, you must subscribe.

Read More

Summary Doximity is a recent hot IPO whose valuation has doubled since its IPO price. The company has developed a platform that counts more than 80% of US physicians as members. Its principal revenue source is selling sales and marketing “modules” to pharma companies, basically as part of a strategy of replacing historical sales processes…

To access this post, you must subscribe.

Read More
{"cart_token":"","hash":"","cart_data":""}